Amgen to Acquire Five Prime for ~$1.9B

 Amgen to Acquire Five Prime for ~$1.9B

Amgen to Acquire Five Prime for ~$1.9B

Shots:

  • Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash, representing an equity value of ~ $1.9B. The transaction is expected to close in Q2’21
  • The acquisition will add Five Prime’s innovative pipeline to Amgen thus expanding its oncology portfolio and supports its international expansion strategy
  • Five Prime’s bemarituzumab complements Amgen’s oncology portfolio. Bemarituzumab, is a first-in-class, P-III ready anti-FGFR2b Ab that demonstrated improvement in PFS, ORR, OS in the frontline treatment of patients with advanced gastric or GEJ cancer in its P-II study

Click here ­to­ read full press release/ article | Ref: PRnewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post